Combination of Autoantibody Signature with PSA Level Enables a Highly Accurate Blood-Based Differentiation of Prostate Cancer Patients from Patients with Benign Prostatic Hyperplasia

Combination of Autoantibody Signature with PSA Level Enables a Highly Accurate Blood-Based Differentiation of Prostate Cancer Patients from Patients with Benign Prostatic Hyperplasia. Leidinger, P., Keller, A., Milchram, L., Harz, C., Hart, M., Werth, A., Lenhof, H. P., Weinhausel, A., Keck, B., Wullich, B., Ludwig, N., & Meese, E. PLoS ONE, 10(6):e0128235, 2015.
bibtex

@Article{pmid26039628,
   Author="Leidinger, P.  and Keller, A.  and Milchram, L.  and Harz, C.  and Hart, M.  and Werth, A.  and Lenhof, H. P.  and Weinhausel, A.  and Keck, B.  and Wullich, B.  and Ludwig, N.  and Meese, E. ",
   Title="{{C}ombination of {A}utoantibody {S}ignature with {P}{S}{A} {L}evel {E}nables a {H}ighly {A}ccurate {B}lood-{B}ased {D}ifferentiation of {P}rostate {C}ancer {P}atients from {P}atients with {B}enign {P}rostatic {H}yperplasia}",
   Journal="PLoS ONE",
   Year="2015",
   Volume="10",
   Number="6",
   Pages="e0128235"
}

Downloads: 0